Telomir Pharmaceuticals (NASDAQ: TELO) has announced new research findings from The Ohio State University College of Veterinary Medicine showing that Telomir-Zn produced growth inhibition across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, led by Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two canine osteosarcoma models. These results support further translational investigation and a potential development pathway using naturally occurring canine osteosarcoma, a strategy that could accelerate drug development by leveraging similarities between canine and human cancers.
The significance of this research lies in its cross-species implications. Osteosarcoma is a rare but aggressive bone cancer that primarily affects children and young adults in humans, and it is also common in dogs, particularly larger breeds. The fact that Telomir-Zn inhibited growth in both human and canine cell lines at comparable low concentrations suggests a shared mechanism of action that could be exploited therapeutically. This opens the door to a dual-purpose development approach: advancing a veterinary treatment for canine osteosarcoma while simultaneously gathering translational data that could inform human clinical trials.
Telomir is in discussions with The Ohio State University College of Veterinary Medicine and is assessing next steps for a potential in vivo efficacy study in canine osteosarcoma. Such a study could provide valuable data on dosing, safety, and efficacy that might be relevant to human patients. The company noted that its immediate focus remains its triple-negative breast cancer program, which is advancing toward site initiation and Phase 1/2 patient enrollment under an active FDA-cleared Investigational New Drug (IND) application for advanced or metastatic triple-negative breast cancer (TNBC). This prioritization reflects a strategic balance: while the osteosarcoma findings are promising, the company is concentrating resources on its lead program in a high-need oncology indication.
For investors, the announcement highlights the broad potential of Telomir-Zn, a small-molecule therapeutic designed to modulate intracellular metal homeostasis and epigenetic regulation. The drug's ability to affect both human and canine cancer cells aligns with its proposed mechanism of action, which targets fundamental pathways involved in cancer growth. If the canine in vivo study proceeds and yields positive results, it could provide a cost-effective and ethically feasible way to gather preclinical data, potentially shortening the timeline to human trials for osteosarcoma. Moreover, success in canine osteosarcoma could pave the way for a veterinary product, creating a revenue stream while supporting the human development program.
The broader context is that osteosarcoma has seen limited therapeutic advances in recent decades, especially for patients with metastatic disease. New treatment options are urgently needed. Telomir-Zn's novel approach, if validated, could offer a new avenue for intervention. However, significant work remains: the current findings are from cell-line models, and in vivo studies are necessary to confirm efficacy and safety. The company's ongoing TNBC program also serves as a test case for the drug's clinical potential, and its progress will be closely watched.
For more details, the full press release can be viewed at https://nnw.fm/laeGH. The latest news and updates relating to TELO are available in the company's newsroom at https://nnw.fm/TELO. NetworkNewsWire, a specialized communications platform, provides financial news and content distribution for private and public companies; more information is available at https://www.NetworkNewsWire.com.
